Search Results

You are looking at 1 - 3 of 3 items for

  • Author: B Portha x
  • Refine by access: All content x
Clear All Modify Search
B. PORTHA
Search for other papers by B. PORTHA in
Google Scholar
PubMed
Close
,
L. PICON
Search for other papers by L. PICON in
Google Scholar
PubMed
Close
, and
G. ROSSELIN
Search for other papers by G. ROSSELIN in
Google Scholar
PubMed
Close

*Laboratoire de Physiologie du Développement, Tour 23/33, Université Paris VII, 2 Place Jussieu, 75005 Paris, France and †Unité de Recherches de Diabétologie et d'Etudes Radio-Immunologlques des Hormones Protéiques, U.55 (INSERM), Hôpital Saint-Antoine, 184 Rue du Faubourg Saint-Antoine, 75012 Paris, France

(Received 1 November 1977)

Experimental prolonged gestation in the rat results in a reduction in the amounts of insulin and glucagon accumulated in the pancreas, a low level of insulin in the plasma and a sharp depletion of hepatic glycogen stores (Portha, Rosselin & Picon, 1976). Moreover, in the liver of the postmature foetus the activities of the main glyconeogenic enzymes, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, are increased (Portha, Le Provost, Picon & Rosselin, 1978). The present study was undertaken to investigate the effects of glucagon in the circulation on these processes.

Gestation was prolonged by s.c. administration of progesterone to the mother (2·5 mg/rat) once daily on days 20·5, 21·5

Restricted access
JC Marie
Search for other papers by JC Marie in
Google Scholar
PubMed
Close
,
D Bailbe
Search for other papers by D Bailbe in
Google Scholar
PubMed
Close
,
E Gylfe
Search for other papers by E Gylfe in
Google Scholar
PubMed
Close
, and
B Portha
Search for other papers by B Portha in
Google Scholar
PubMed
Close

We examined to what extent the abnormal glucose-dependent insulin secretion observed in NIDDM (non-insulin-dependent diabetes mellitus) is related to alterations in the handling of cytosolic Ca2+ of islets of Langerhans. Using two recognized rat models of NIDDM, the GK (Goto-Kakizaki) spontaneous model and the nSTZ (neonatal streptozotocin) induced model, we could detect several common alterations in the glucose-induced [Ca2+]i cytosolic responses. First, the initial reduction of [Ca2+]i following high glucose (16.7 mM) observed routinely in islets obtained from non-diabetic Wistar rats could not be detected in GK and nSTZ islets. Second, a delayed response for glucose to induce a subsequent 3% increase of [Ca2+]i over basal level was observed in both GK (321+/-40 s, n=11) and nSTZ (326+/-38 s, n=13) islets as compared with Wistar islets (198+/-20 s, n=11), values representing means+/-s.e.m. Third, the rate of increase in [Ca2+]i in response to a high glucose challenge was 25% and 40% lower in GK and nSTZ respectively, as compared with Wistar islets. Fourth, the maximal [Ca2+](i) level reached after 10 min of perifusion with 16.7 mM glucose was lower with GK and nSTZ islets and represented respectively 60% and 90% of that of Wistar islets. Further, thapsigargin, a blocker of Ca2+/ATPases (SERCA), abolished the initial reduction in [Ca2+]i observed in response to high glucose and induced fast [Ca2+]i oscillations with high amplitude in Wistar islets. The latter effect was not seen in GK and nSTZ islets. In these two NIDDM models, several common alterations in glucose-induced Ca2+ handling were revealed which may contribute to their poor glucose-induced insulin secretion.

Free access
N Dachicourt
Search for other papers by N Dachicourt in
Google Scholar
PubMed
Close
,
P Serradas
Search for other papers by P Serradas in
Google Scholar
PubMed
Close
,
D Bailbe
Search for other papers by D Bailbe in
Google Scholar
PubMed
Close
,
M Kergoat
Search for other papers by M Kergoat in
Google Scholar
PubMed
Close
,
L Doare
Search for other papers by L Doare in
Google Scholar
PubMed
Close
, and
B Portha
Search for other papers by B Portha in
Google Scholar
PubMed
Close

The effects of glucagon-like peptide-1(7-36)-amide (GLP-1) on cAMP content and insulin release were studied in islets isolated from diabetic rats (n0-STZ model) which exhibited impaired glucose-induced insulin release. We first examined the possibility of re-activating the insulin response to glucose in the beta-cells of the diabetic rats using GLP-1 in vitro. In static incubation experiments, GLP-1 amplified cAMP accumulation (by 170%) and glucose-induced insulin release (by 140%) in the diabetic islets to the same extent as in control islets. Using a perifusion procedure, GLP-1 amplified the insulin response to 16.7 mM glucose by diabetic islets and generated a clear biphasic pattern of insulin release. The incremental insulin response to glucose in the presence of GLP-1, although lower than corresponding control values (1.56 +/- 0.37 and 4.53 +/- 0.60 pg/min per ng islet DNA in diabetic and control islets respectively), became similar to that of control islets exposed to 16.7 mM glucose alone (1.09 +/- 0.15 pg/min per ng islet DNA). Since in vitro GLP-1 was found to exert positive effects on the glucose competence of the residual beta-cells in the n0-STZ model. we investigated the therapeutic effect of in vivo GLP-1 administration on glucose tolerance and glucose-induced insulin release by n0-STZ rats. An infusion of GLP-1 (10 ng/min per kg; i.v.) in n0-STZ rats enhanced significantly (P < 0.01) basal plasma insulin levels, and, when combined with an i.v. glucose tolerance and insulin secretion test, it was found to improve (P < 0.05) glucose tolerance and the insulinogenic index, as compared with the respective values of these parameters before GLP-1 treatment.

Restricted access